<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathogenesis and pathophysiology of bacterial meningitis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathogenesis and pathophysiology of bacterial meningitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathogenesis and pathophysiology of bacterial meningitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rodrigo Hasbun, MD, MPH, FIDSA</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allan R Tunkel, MD, PhD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 09, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>From its original recognition in 1805 until the early 1900s, bacterial meningitis due to <em>Haemophilus influenzae</em> and <em>Streptococcus pneumoniae</em> was virtually 100 percent fatal. In 1913, Simon Flexner's introduction of intrathecal meningococcal antiserum decreased the mortality of meningococcal meningitis from 75 to 31 percent, but the clinical outcome did not dramatically improve for all three meningeal pathogens until the advent of systemic antimicrobial therapy in the 1930s [<a href="#rid1">1</a>].</p><p>Despite the effectiveness of antibiotics in clearing bacteria from the cerebrospinal fluid (CSF), bacterial meningitis in adults continues to cause significant morbidity and mortality worldwide. As an example, in the largest prospective study to date of 1412 episodes of community-acquired bacterial meningitis, the case-fatality rate was 17 percent, and unfavorable outcomes occurred in 38 percent [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/1291.html" rel="external">"Neurologic complications of bacterial meningitis in adults"</a>.)</p><p>The pathogenesis and pathophysiology of bacterial meningitis involve a complex interplay between virulence factors of the pathogens and the host immune response [<a href="#rid3">3,4</a>]. Much of the damage from this infection is believed to result from cytokines released within the CSF as the host mounts an inflammatory response. (See  <a class="medical medical_review" href="/d/html/1291.html" rel="external">"Neurologic complications of bacterial meningitis in adults"</a>.)</p><p>The clinically important issues related to the pathogenesis and pathophysiology of bacterial meningitis will be reviewed here. The clinical features, treatment, prognosis, and prevention of bacterial meningitis in adults and children and issues related to chronic and recurrent meningitis are discussed separately. (See  <a class="medical medical_review" href="/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults"</a> and  <a class="medical medical_review" href="/d/html/1290.html" rel="external">"Initial therapy and prognosis of community-acquired bacterial meningitis in adults"</a> and  <a class="medical medical_review" href="/d/html/1283.html" rel="external">"Treatment of bacterial meningitis caused by specific pathogens in adults"</a> and  <a class="medical medical_review" href="/d/html/5968.html" rel="external">"Bacterial meningitis in children older than one month: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6010.html" rel="external">"Bacterial meningitis in children older than one month: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/1275.html" rel="external">"Approach to the patient with chronic meningitis"</a> and  <a class="medical medical_review" href="/d/html/3908.html" rel="external">"Approach to the adult with recurrent infections", section on 'Meningitis'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Bacterial meningitis develops when virulence factors of the pathogen overcome host defense mechanisms [<a href="#rid3">3,5</a>]. </p><p>The pathogenesis of bacterial meningitis for the most common meningeal pathogens<em> (S. pneumoniae, Neisseria meningitidis, H. influenzae, Group B streptococcus </em>[GB<em>S</em>]<em>, Escherichia coli</em>) have four main processes [<a href="#rid3">3,4</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Colonization of respiratory, gastrointestinal, or lower genital tract </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Invasion of the bloodstream</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Survival in the bloodstream</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Entry into the subarachnoid space</p><p></p><p>(See  <a class="medical medical_review" href="/d/html/1276.html" rel="external">"Microbiology and pathobiology of Neisseria meningitidis"</a> and  <a class="medical medical_review" href="/d/html/1298.html" rel="external">"Epidemiology of Neisseria meningitidis infection"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Colonization of mucous membranes</span><span class="headingEndMark"> — </span>Many of the major meningeal pathogens possess surface components, such as fimbriae or pili, which enhance mucosal colonization. The main requirement for meningococcal adhesion is type IV pili, which adhere via various receptors including platelet-activating factor receptor (PAFR), beta-2 adrenergic receptors, and CD147 [<a href="#rid5">5</a>]; the outer membrane proteins (OpC and OpA) have also been proposed to contribute to the maintenance of adhesion [<a href="#rid3">3</a>]. In <em>S. pneumoniae</em>, the three receptors that are responsible for adhesion to epithelial surfaces are PAFR, laminin receptors, and polymeric immunoglobulin receptor [<a href="#rid6">6</a>]. Colonization of the host mucosal epithelium is facilitated by evasion of mucosal secretory immunoglobulin A (IgA) through pathogen secretion of IgA protease [<a href="#rid7">7</a>]. IgA protease inactivates the mucosal antibody and facilitates bacterial attachment to host epithelial cells. After successful colonization, invasion occurs across the epithelium via intracellular or intercellular pathways that are mediated by specific binding adhesins of the bacterial surface, many of which are localized to pili in gram-negative pathogens [<a href="#rid8">8</a>]. After attachment and aggregation of <em>N. meningitidis</em>, organisms detach from the aggregates to systematically invade the host by means of a transcellular pathway that crosses the respiratory epithelium [<a href="#rid9">9</a>]. Surface encapsulation may also be an important virulence factor for nasopharyngeal colonization and systemic invasion of meningeal pathogens.</p><p class="headingAnchor" id="H3119785500"><span class="h2">Invasion of bloodstream</span><span class="headingEndMark"> — </span>Colonization with the meningeal pathogens is much more common than invasion of the bloodstream and subsequent meningitis<strong>.</strong> Bloodstream invasion is most likely mediated by an interaction of environmental, host factors, and genetic factors of the pathogens [<a href="#rid4">4</a>]. Environmental factors include prior viral infection (eg, influenza), smoking, and alcohol abuse while host factors include asplenia, complement deficiency, antibody deficiency, and immunosuppressive therapy or conditions [<a href="#rid6">6</a>]. </p><p>Genetic factors related to host response to bacterial infections that have been described to predispose to infection are single-nucleotide polymorphisms (SNPs) in nuclear factor kB inhibitor alpha in pneumococcal meningitis [<a href="#rid6">6</a>] or deficiencies in interleukin-1 receptor-associated kinase 4, myeloid differentiation primary response protein 88, and SNPs in pattern recognition receptor genes, such as Toll-like receptor 9 [<a href="#rid6">6,10</a>]. Furthermore, multilocus sequence typing has described hyperinvasive strains of <em>N. meningitidis</em> [<a href="#rid11">11</a>], <em>S. pneumoniae</em> [<a href="#rid12">12</a>], GBS [<a href="#rid13">13</a>], and <em>E. coli</em> [<a href="#rid14">14</a>]. </p><p class="headingAnchor" id="H4"><span class="h2">Intravascular survival</span><span class="headingEndMark"> — </span>Following invasion and entry into the bloodstream, the polysaccharide capsule of the main meningeal pathogens (<em>S. pneumoniae, N. meningitidis, H. influenzae</em>, GBS, and <em>E. coli</em>) serves as the main line of defense by inhibiting the surface depositions of adhesins (eg, complement factors) thus preventing phagocytosis [<a href="#rid4">4</a>]. The meningococcal capsule can also inhibit the classical complement pathway by decreasing the surface deposition of the complement component C-4 binding protein [<a href="#rid15">15</a>]. Complement factor H is a complement regulatory protein inhibiting alternative pathway activation with low levels associated with mortality in pneumococcal meningitis [<a href="#rid16">16</a>]. In addition to the capsule, several bacterial surface molecules such as factor H binding protein, neisserial surface protein A, and porin B in <em>N. meningitidis</em> target specific complement components [<a href="#rid17">17</a>]. The pathogens avoid the bactericidal activity of complement, survive in the bloodstream, and cross the blood-brain barrier into the cerebrospinal fluid (CSF).</p><p class="headingAnchor" id="H5"><span class="h2">Meningeal invasion</span><span class="headingEndMark"> — </span>Bacterial penetration to the subarachnoid space is facilitated by the duration and degree of bacteremia and occurs by the interaction of bacteria with the endothelial cells of the blood-CSF barrier in the postcapillary veins [<a href="#rid6">6</a>]. More recent studies suggest that counteracting targets contributing to the bacterial invasion of the blood-brain barrier may improve outcomes [<a href="#rid6">6</a>]. </p><p>In both <em>H. influenzae</em> and <em>S. pneumoniae</em>, there is evidence that the choroid plexus may be the site of the initial entry of the bacteria into the ventricle with subsequent spread throughout the CSF [<a href="#rid18">18,19</a>]. Adhesion to the laminin receptors on the brain endothelial cells is mediated by the binding of the bacterial adhesins: the pneumococcal surface protein f<em>or S. pneumoniae</em> and the outer membrane protein porin A f<em>or N. meningitidis</em> [<a href="#rid20">20</a>]. The process of adhesion also involves the PAFR on the endothelial cell surfaces facilitating the invasion by <em>S. pneumoniae</em> (through transcellular mechanism) and<em> N. meningitidis</em> (via paracellular passage) [<a href="#rid21">21</a>]. After adhesion<em>, N. meningitidis</em> utilizes its type IV pilus to activate beta2-adrenoreceptors to organize cortical plaques that prevents complement-mediated lysis and facilitates the opening of the interendothelial junctions that allows for the paracellular migration of the bacteria into the CSF [<a href="#rid22">22</a>].</p><p>Upon successful invasion of the CSF, bacteria can multiply to high concentrations within hours (eg, up to 10<sup>7</sup> organisms per milliliter) because of inadequate humoral immunity in the CSF [<a href="#rid3">3</a>]. Specifically, low concentrations of immunoglobulin and complement within human CSF (usually 1000-fold lower than serum) result in poor opsonic activity, successful bacterial replication, and the subsequent development of inflammation [<a href="#rid23">23</a>]. Despite an early influx of leukocytes in bacterial meningitis, host defenses in CSF remain suboptimal because of the lack of functional opsonic and bactericidal activity. </p><p>The accumulation of neutrophils in the CSF is mainly driven by the anaphylatoxin complement component 5a (C5a) and is correlated with disease severity and outcomes. The use of C5a receptor blockers is a promising adjunctive therapy, as they reduce inflammation and improve outcomes [<a href="#rid24">24</a>]. An additional complement-blocking target (mannose-binding lectin-associated serine protease 2 [MASP-2]) by monoclonal antibodies has also been found to attenuate the inflammatory response in pneumococcal meningitis [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H6"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The clinical disease observed when bacteria enter the cerebrospinal fluid (CSF) is a result of a complex interaction of components of the bacteria and the host inflammatory response. This interaction influences both the blood-brain barrier and neuronal integrity.</p><p class="headingAnchor" id="H7"><span class="h2">Contribution of cell wall components</span><span class="headingEndMark"> — </span>As bacteria begin to die, especially after the exposure to antibiotic therapy, bacterial fragments interact with pattern recognition receptors that trigger the host immune response [<a href="#rid26">26</a>]. In experimental animal models, subcapsular bacterial surface components are most important for the induction of CSF inflammation and blood-brain barrier injury. As an example, purified pneumococcal cell wall but not purified capsular polysaccharide induced CSF inflammation similar to live pneumococci when experimentally injected into the cisterna magna of rabbits [<a href="#rid27">27</a>]. Both teichoic acid and peptidoglycan, which are cell wall constituents, were able to provoke this inflammatory response, although the kinetics of the response differed (maximal response to teichoic acid at 5 hours and to peptidoglycan between 5 and 24 hours) [<a href="#rid28">28</a>]. Immune recognition of these bacterial components results in a strong inflammatory response, leading to blood-brain barrier impairment due to recruitment of leukocytes, vascular deregulation, vasculitis, and occlusion of vessels, which cause increased intracranial pressure [<a href="#rid5">5</a>]. In patients with pneumococcal meningitis, high pneumococcal cell wall burden as measured by CSF lipoteichoic acid has been correlated with adverse clinical outcomes [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Generation of inflammatory cytokines</span><span class="headingEndMark"> — </span>Inhibition of many steps in the inflammatory cascade, such as neutrophil recruitment, improves the clinical outcome in meningitis by reducing neuronal loss [<a href="#rid5">5</a>]. The only clinically-proven adjunctive therapy to ameliorate this inflammatory response and to improve mortality in high-income countries with pneumococcal meningitis is <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> [<a href="#rid30">30,31</a>]. After the recommendation of using adjunctive dexamethasone by the Infectious Diseases Society of America in adults with bacterial meningitis [<a href="#rid32">32</a>], studies in the Netherlands and in the United States have documented a significant reduction in mortality in pneumococcal meningitis [<a href="#rid30">30,31</a>]. (See  <a class="medical medical_review" href="/d/html/1299.html" rel="external">"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults", section on 'Developed regions'</a>.) </p><p>Other promising adjunctive therapies that have been evaluated in the animal model include complement inhibitors (eg, anti-C5 antibodies), matrix-metalloproteinase inhibitors (eg, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>), and nonbacteriolytic antibiotics (eg, <a class="drug drug_general" data-topicid="9304" href="/d/drug information/9304.html" rel="external">daptomycin</a>) but need validation in clinical studies [<a href="#rid33">33</a>].</p><p>Surface bound Toll-like receptors and cytosolic nucleotide-binding oligomerization domain-like receptors act as sensors for cytoplasmic pathogen-associated molecular patterns and stimulate the inflammatory response [<a href="#rid6">6</a>]. Proinflammatory cytokines such as tumor necrosis factor alpha, interleukin (IL)-6, and IL-1beta are released in higher quantities in pneumococcal meningitis than in other meningeal pathogens and can explain with worse prognosis seen with this pathogen [<a href="#rid34">34</a>]. Matrix metalloproteinase-9 is released from leukocytes in the CSF and is involved in increasing proinflammatory cytokines, degradation of extracellular matrix components, and recruiting more leukocytes into the CSF [<a href="#rid3">3</a>]. Patients with pneumococcal meningitis also show higher levels of matrix metalloproteinases, anti-inflammatory cytokines (eg, IL-10 and transforming growth factor-beta), and chemokines (eg, IL-8, macrophage inflammatory protein-1a, and monocyte chemoattractant protein-1) [<a href="#rid5">5</a>]. High bacterial density and bacterial breakdown products that may also be generated after treatment with bacteriolytic antibiotics promote higher concentrations of inflammatory mediators, which lead to a higher likelihood of neurologic sequelae and severe disease. These cytokines act in conjunction with bacterial surface components, such as lipopolysaccharides, to induce the synthesis of adhesive glycoproteins on the luminal surface of cerebral endothelium [<a href="#rid35">35,36</a>]. These adhesive glycoproteins, such as selectins and intercellular adhesion molecule-1, facilitate localized adhesion and diapedesis of neutrophils into the CSF. Some experimental evidence suggests that use of nonbacteriolytic antibiotics, which reduce the proinflammatory response triggered by cell-wall components, prevent neuronal damage [<a href="#rid37">37</a>], although more studies are needed.</p><p>Once inflammation is initiated, a series of injuries occur to the endothelium of the blood-brain barrier (eg, separation of intercellular tight junctions) that result in vasogenic brain edema, loss of cerebrovascular autoregulation, and increased intracranial pressure [<a href="#rid6">6</a>]. The clinical expressions of these pathophysiologic events are the neurologic complications of meningitis including coma, hydrocephalus, seizures, deafness, and motor, sensory, and cognitive deficits. Histopathologically, autopsy studies show brain edema, hydrocephalus, petechial hemorrhages, necrotic lesions in the cortical and subcortical structures, loss of myelinated fibers in the white matter, and hippocampal apoptosis [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/d/html/1291.html" rel="external">"Neurologic complications of bacterial meningitis in adults"</a>.)</p><p class="headingAnchor" id="H20298351"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>The pathogenesis and pathophysiology of bacterial meningitis involve a complex interplay between virulence factors of the pathogens and the host immune response. Much of the damage from this infection is believed to result from cytokines released within the cerebrospinal fluid (CSF) as the host mounts an inflammatory response. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bacterial meningitis develops when virulence factors of the pathogen overcome host defense mechanisms. For the most common pathogens causing bacterial meningitis in adults, such as <em>Streptococcus pneumoniae</em> and <em>Neisseria meningitidis</em>, meningeal invasion is related to several virulence factors that allow the bacteria to colonize host mucosal epithelium, invade and survive within the bloodstream, cross the blood-brain barrier, and multiply within the CSF. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In experimental animal models, subcapsular bacterial surface components are most important for the induction of CSF inflammation and blood-brain barrier injury. (See <a class="local">'Contribution of cell wall components'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some studies suggest that the mechanism by which these meningeal pathogens induce an inflammatory response and blood-brain barrier injury is through the in situ generation of inflammatory cytokines (eg, interleukin-1 [IL-1], IL-6, and tumor necrosis factor-alpha) and matrix metalloproteinases within the CSF. (See <a class="local">'Generation of inflammatory cytokines'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Once inflammation is initiated, a series of injuries occur to the endothelium of the blood-brain barrier (eg, separation of intercellular tight junctions) that result in vasogenic brain edema, loss of cerebrovascular autoregulation, and increased intracranial pressure. This results in localized areas of brain ischemia, cytotoxic injury, and neuronal apoptosis. (See <a class="local">'Generation of inflammatory cytokines'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">Dexamethasone</a> in adults with pneumococcal meningitis in resource-rich countries is the only clinically proven adjunctive therapy to reduce mortality, but other therapies such as matrix metalloproteinase inhibitors, anti-C 5 antibodies, monoclonal antibodies targeting mannose-binding lectin-associated serine protease 2 (MASP-2), and nonbacteriolytic antibiotics show promising results in the animal model. (See  <a class="medical medical_review" href="/d/html/1299.html" rel="external">"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults", section on 'Developed regions'</a> and <a class="local">'Generation of inflammatory cytokines'</a> above.) </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Schwentker FF, Gelman S, Long PH. Landmark article April 24, 1937. The treatment of meningococcic meningitis with sulfanilamide. Preliminary report. By Francis F. Schwentker, Sidney Gelman, and Perrin H. Long. JAMA 1984; 251:788.</a></li><li><a class="nounderline abstract_t">Bijlsma MW, Brouwer MC, Kasanmoentalib ES, et al. Community-acquired bacterial meningitis in adults in the Netherlands, 2006-14: a prospective cohort study. Lancet Infect Dis 2016; 16:339.</a></li><li><a class="nounderline abstract_t">McGill F, Heyderman RS, Panagiotou S, et al. Acute bacterial meningitis in adults. Lancet 2016; 388:3036.</a></li><li><a class="nounderline abstract_t">van de Beek D, Brouwer M, Hasbun R, et al. Community-acquired bacterial meningitis. Nat Rev Dis Primers 2016; 2:16074.</a></li><li><a class="nounderline abstract_t">Doran KS, Fulde M, Gratz N, et al. Host-pathogen interactions in bacterial meningitis. Acta Neuropathol 2016; 131:185.</a></li><li><a class="nounderline abstract_t">Kim KS. Investigating Bacterial Penetration of the Blood-Brain Barrier for the Pathogenesis, Prevention, and Therapy of Bacterial Meningitis. ACS Infect Dis 2020; 6:34.</a></li><li><a class="nounderline abstract_t">Plaut AG. The IgA1 proteases of pathogenic bacteria. Annu Rev Microbiol 1983; 37:603.</a></li><li><a class="nounderline abstract_t">Stephens DS, Farley MM. Pathogenic events during infection of the human nasopharynx with Neisseria meningitidis and Haemophilus influenzae. Rev Infect Dis 1991; 13:22.</a></li><li><a class="nounderline abstract_t">Quagliarello V. Dissemination of Neisseria meningitidis. N Engl J Med 2011; 364:1573.</a></li><li><a class="nounderline abstract_t">Picard C, von Bernuth H, Ghandil P, et al. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine (Baltimore) 2010; 89:403.</a></li><li><a class="nounderline abstract_t">Read RC. Neisseria meningitidis; clones, carriage, and disease. Clin Microbiol Infect 2014; 20:391.</a></li><li><a class="nounderline abstract_t">Weinberger DM, Harboe ZB, Sanders EA, et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 2010; 51:692.</a></li><li><a class="nounderline abstract_t">Tazi A, Disson O, Bellais S, et al. The surface protein HvgA mediates group B streptococcus hypervirulence and meningeal tropism in neonates. J Exp Med 2010; 207:2313.</a></li><li><a class="nounderline abstract_t">Kim KS. Pathogenesis of bacterial meningitis: from bacteraemia to neuronal injury. Nat Rev Neurosci 2003; 4:376.</a></li><li><a class="nounderline abstract_t">Agarwal S, Vasudhev S, DeOliveira RB, Ram S. Inhibition of the classical pathway of complement by meningococcal capsular polysaccharides. J Immunol 2014; 193:1855.</a></li><li><a class="nounderline abstract_t">Kasanmoentalib ES, Valls Serón M, Engelen-Lee JY, et al. Complement factor H contributes to mortality in humans and mice with bacterial meningitis. J Neuroinflammation 2019; 16:279.</a></li><li><a class="nounderline abstract_t">Johswich KO, Zhou J, Law DK, et al. Invasive potential of nonencapsulated disease isolates of Neisseria meningitidis. Infect Immun 2012; 80:2346.</a></li><li><a class="nounderline abstract_t">Daum RS, Scheifele DW, Syriopoulou VP, et al. Ventricular involvement in experimental Hemophilus influenzae meningitis. J Pediatr 1978; 93:927.</a></li><li><a class="nounderline abstract_t">Prager O, Friedman A, Nebenzahl YM. Role of neural barriers in the pathogenesis and outcome of Streptococcus pneumoniae meningitis. Exp Ther Med 2017; 13:799.</a></li><li><a class="nounderline abstract_t">Orihuela CJ, Mahdavi J, Thornton J, et al. Laminin receptor initiates bacterial contact with the blood brain barrier in experimental meningitis models. J Clin Invest 2009; 119:1638.</a></li><li><a class="nounderline abstract_t">Bernard SC, Simpson N, Join-Lambert O, et al. Pathogenic Neisseria meningitidis utilizes CD147 for vascular colonization. Nat Med 2014; 20:725.</a></li><li><a class="nounderline abstract_t">Coureuil M, Bourdoulous S, Marullo S, Nassif X. Invasive meningococcal disease: a disease of the endothelial cells. Trends Mol Med 2014; 20:571.</a></li><li><a class="nounderline abstract_t">Koedel U, Scheld WM, Pfister HW. Pathogenesis and pathophysiology of pneumococcal meningitis. Lancet Infect Dis 2002; 2:721.</a></li><li><a class="nounderline abstract_t">Koelman DLH, Brouwer MC, van de Beek D. Targeting the complement system in bacterial meningitis. Brain 2019; 142:3325.</a></li><li><a class="nounderline abstract_t">Kasanmoentalib ES, Seron MV, Ferwerda B, et al. Erratum to: Mannose-binding lectin-associated serine protease 2 (MASP-2) contributes to poor disease outcome in humans and mice with pneumococcal meningitis. J Neuroinflammation 2017; 14:77.</a></li><li><a class="nounderline abstract_t">Chiavolini D, Pozzi G, Ricci S. Animal models of Streptococcus pneumoniae disease. Clin Microbiol Rev 2008; 21:666.</a></li><li><a class="nounderline abstract_t">Tuomanen E, Tomasz A, Hengstler B, Zak O. The relative role of bacterial cell wall and capsule in the induction of inflammation in pneumococcal meningitis. J Infect Dis 1985; 151:535.</a></li><li><a class="nounderline abstract_t">Tuomanen E, Liu H, Hengstler B, et al. The induction of meningeal inflammation by components of the pneumococcal cell wall. J Infect Dis 1985; 151:859.</a></li><li><a class="nounderline abstract_t">Schneider O, Michel U, Zysk G, et al. Clinical outcome in pneumococcal meningitis correlates with CSF lipoteichoic acid concentrations. Neurology 1999; 53:1584.</a></li><li><a class="nounderline abstract_t">Brouwer MC, Heckenberg SG, de Gans J, et al. Nationwide implementation of adjunctive dexamethasone therapy for pneumococcal meningitis. Neurology 2010; 75:1533.</a></li><li><a class="nounderline abstract_t">Hasbun R, Rosenthal N, Balada-Llasat JM, et al. Epidemiology of Meningitis and Encephalitis in the United States, 2011-2014. Clin Infect Dis 2017; 65:359.</a></li><li><a class="nounderline abstract_t">Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267.</a></li><li><a class="nounderline abstract_t">Bewersdorf JP, Grandgirard D, Koedel U, Leib SL. Novel and preclinical treatment strategies in pneumococcal meningitis. Curr Opin Infect Dis 2018; 31:85.</a></li><li><a class="nounderline abstract_t">Grandgirard D, Gäumann R, Coulibaly B, et al. The causative pathogen determines the inflammatory profile in cerebrospinal fluid and outcome in patients with bacterial meningitis. Mediators Inflamm 2013; 2013:312476.</a></li><li><a class="nounderline abstract_t">Moser R, Schleiffenbaum B, Groscurth P, Fehr J. Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J Clin Invest 1989; 83:444.</a></li><li><a class="nounderline abstract_t">Quagliarello V, Scheld WM. Bacterial meningitis: pathogenesis, pathophysiology, and progress. N Engl J Med 1992; 327:864.</a></li><li><a class="nounderline abstract_t">Grandgirard D, Schürch C, Cottagnoud P, Leib SL. Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. Antimicrob Agents Chemother 2007; 51:2173.</a></li><li><a class="nounderline abstract_t">Engelen-Lee JY, Brouwer MC, Aronica E, van de Beek D. Pneumococcal meningitis: clinical-pathological correlations (MeninGene-Path). Acta Neuropathol Commun 2016; 4:26.</a></li></ol></div><div id="topicVersionRevision">Topic 1289 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6363729" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Landmark article April 24, 1937. The treatment of meningococcic meningitis with sulfanilamide. Preliminary report. By Francis F. Schwentker, Sidney Gelman, and Perrin H. Long.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26652862" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Community-acquired bacterial meningitis in adults in the Netherlands, 2006-14: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27265346" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Acute bacterial meningitis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27808261" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Community-acquired bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26744349" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Host-pathogen interactions in bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31805229" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Investigating Bacterial Penetration of the Blood-Brain Barrier for the Pathogenesis, Prevention, and Therapy of Bacterial Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6416146" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The IgA1 proteases of pathogenic bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1901998" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pathogenic events during infection of the human nasopharynx with Neisseria meningitidis and Haemophilus influenzae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21506747" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Dissemination of Neisseria meningitidis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21057262" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24766477" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Neisseria meningitidis; clones, carriage, and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20715907" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20956545" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The surface protein HvgA mediates group B streptococcus hypervirulence and meningeal tropism in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12728265" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pathogenesis of bacterial meningitis: from bacteraemia to neuronal injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25015832" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Inhibition of the classical pathway of complement by meningococcal capsular polysaccharides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31883521" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Complement factor H contributes to mortality in humans and mice with bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22508859" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Invasive potential of nonencapsulated disease isolates of Neisseria meningitidis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/102754" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Ventricular involvement in experimental Hemophilus influenzae meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28450902" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Role of neural barriers in the pathogenesis and outcome of Streptococcus pneumoniae meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19436113" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Laminin receptor initiates bacterial contact with the blood brain barrier in experimental meningitis models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24880614" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pathogenic Neisseria meningitidis utilizes CD147 for vascular colonization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25178566" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Invasive meningococcal disease: a disease of the endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12467688" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pathogenesis and pathophysiology of pneumococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31373605" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Targeting the complement system in bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28385159" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Erratum to: Mannose-binding lectin-associated serine protease 2 (MASP-2) contributes to poor disease outcome in humans and mice with pneumococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18854486" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Animal models of Streptococcus pneumoniae disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3973407" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The relative role of bacterial cell wall and capsule in the induction of inflammation in pneumococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3989321" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The induction of meningeal inflammation by components of the pneumococcal cell wall.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10534274" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical outcome in pneumococcal meningitis correlates with CSF lipoteichoic acid concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20881273" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Nationwide implementation of adjunctive dexamethasone therapy for pneumococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28419350" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Epidemiology of Meningitis and Encephalitis in the United States, 2011-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15494903" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Practice guidelines for the management of bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29095719" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Novel and preclinical treatment strategies in pneumococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23864766" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The causative pathogen determines the inflammatory profile in cerebrospinal fluid and outcome in patients with bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2643630" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1508247" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Bacterial meningitis: pathogenesis, pathophysiology, and progress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17371820" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27001057" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pneumococcal meningitis: clinical-pathological correlations (MeninGene-Path).</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
